- Home
- MBC vs MESO Comparison
MBC vs MESO Comparison
Compare MBC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- MESO
- Stock Information
- Founded
- MBC 1954
- MESO 2004
- Country
- MBC United States
- MESO Australia
- Employees
- MBC N/A
- MESO N/A
- Industry
- MBC Agricultural Chemicals
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBC Industrials
- MESO Health Care
- Exchange
- MBC Nasdaq
- MESO Nasdaq
- Market Cap
- MBC 1.4B
- MESO 1.4B
- IPO Year
- MBC N/A
- MESO N/A
- Fundamental
- Price
- MBC $10.20
- MESO $10.44
- Analyst Decision
- MBC Strong Buy
- MESO Buy
- Analyst Count
- MBC 1
- MESO 4
- Target Price
- MBC $15.00
- MESO $18.00
- AVG Volume (30 Days)
- MBC 779.8K
- MESO 191.2K
- Earning Date
- MBC 08-05-2025
- MESO 02-26-2025
- Dividend Yield
- MBC N/A
- MESO N/A
- EPS Growth
- MBC N/A
- MESO N/A
- EPS
- MBC 0.77
- MESO N/A
- Revenue
- MBC $2,722,600,000.00
- MESO $5,670,000.00
- Revenue This Year
- MBC N/A
- MESO $178.09
- Revenue Next Year
- MBC $4.37
- MESO $305.06
- P/E Ratio
- MBC $13.23
- MESO N/A
- Revenue Growth
- MBC 1.30
- MESO N/A
- 52 Week Low
- MBC $9.63
- MESO $5.78
- 52 Week High
- MBC $20.67
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- MBC 45.26
- MESO 40.14
- Support Level
- MBC $9.86
- MESO $11.70
- Resistance Level
- MBC $10.35
- MESO $12.37
- Average True Range (ATR)
- MBC 0.39
- MESO 0.44
- MACD
- MBC 0.03
- MESO -0.04
- Stochastic Oscillator
- MBC 37.50
- MESO 6.88
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.